Stocks · News reference

Hyperfine Announces Peer-Reviewed Publications In Journal Of Neurosurgery And Stroke Supporting Swoop Portable MRI In Neurosurgical And Stroke Care Settings

Jul 30, 2026, 12:17 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 12:18 PMBenzinga Newsdesk
Hyperfine Announces Peer-Reviewed Publication Of NEURO PMR Study In Journal Of Neuroimaging
Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applicationsHyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology
Read original at benzinga
HYPR
BenzingaAug 20, 2026, 12:17 PMBenzinga Newsdesk
Hyperfine Receives FDA Clearance For Its Latest Optive AI Software Update; Plans Rollout Of New Software In The U.S. In September
This advancement is Hyperfine’s second FDA-cleared software package since the launch of its next-generation Swoop system in mid-2025. It builds on Hyperfine’s Optive AI software to deliver even higher image quality in
Read original at benzinga
HYPR
BenzingaAug 10, 2026, 4:58 PMBenzinga Newsdesk
B. Riley Securities Reiterates Buy on Hyperfine, Lowers Price Target to $1.6
B. Riley Securities analyst Yuan Zhi reiterates Hyperfine (NASDAQ:HYPR) with a Buy and lowers the price target from $2 to $1.6.
Read original at benzinga
HYPR
BenzingaAug 6, 2026, 8:16 PMBenzinga Newsdesk
Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est
Hyperfine (NASDAQ:HYPR) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.
Read original at benzinga
HYPR